Your request to link to rcsb for Serine/threonine-protein kinase B-raf

---

• 1UWH: the complex of wild type b-raf and bay439006
• 1UWJ: the complex of mutant v599e b-raf and bay439006
• 2FB8: structure of the b-raf kinase domain bound to sb-590885
• 2L05: solution nmr structure of the ras-binding domain of serine/threonine- protein kinase b-raf from homo sapiens, northeast structural genomics consortium target hr4694f
• 3C4C: b-raf kinase in complex with plx4720
• 3D4Q: pyrazole-based inhibitors of b-raf kinase
• 3IDP: b-raf v600e kinase domain in complex with an aminoisoquinoline inhibitor
• 3II5: the complex of wild-type b-raf with pyrazolo pyrimidine inhibitor
• 3NY5: crystal structure of the rbd domain of serine/threonine-protein kinase b-raf from homo sapiens. northeast structural genomics consortium target hr4694f
• 3OG7: b-raf kinase v600e oncogenic mutant in complex with plx4032
• 3PPJ: human b-raf kinase in complex with a furopyridine inhibitor
• 3PPK: human b-raf kinase in complex with a non-oxime furopyridine inhibitor
• 3PRF: crystal structure of human b-raf kinase domain in complex with a non- oxime furopyridine inhibitor
• 3PRI: crystal structure of human b-raf kinase in complex with a non-oxime furopyridine inhibitor
• 3PSB: furo[2,3-c]pyridine-based indanone oximes as potent and selective b- raf inhibitors
• 3PSD: non-oxime pyrazole based inhibitors of b-raf kinase
• 3Q4C: crystal structure of wild type braf kinase domain in complex with organometallic inhibitor cns292
• 3Q96: b-raf kinase domain in complex with a tetrahydronaphthalene inhibitor
• 3SKC: human b-raf kinase in complex with an amide linked pyrazolopyridine inhibitor
• 3TV4: human b-raf kinase domain in complex with an bromopyridine benzamide inhibitor
• 3TV6: human b-raf kinase domain in complex with a methoxypyrazolopyridinyl benzamide inhibitor
• 4CQE: b-raf kinase v600e mutant in complex with a diarylthiazole b-raf inhibitor
• 4DBN: crystal structure of the kinase domain of human b-raf with a [1, 3]thiazolo[5,4-b]pyridine derivative
• 4E26: braf in complex with an organic inhibitor 7898734
• 4E4X: crystal structure of b-raf kinase domain in complex with a dihydropyrido[2,3-d]pyrimidinone-based inhibitor
• 4EHE: b-raf kinase domain in complex with an aminothienopyrimidine-based inhibitor
• 4EHG: b-raf kinase domain in complex with an aminopyridimine-based inhibitor
• 4FC0: crystal structure of human kinase domain of b-raf with a dfg-out inhibitor
• 4FK3: b-raf kinase v600e oncogenic mutant in complex with plx3203
• 4G9C: human b-raf kinase domain bound to a type ii pyrazolopyridine inhibitor
• 4G9R: b-raf v600e kinase domain bound to a type ii dihydroquinazoline inhibitor
• 4H58: braf in complex with compound 3
• 4JVG: b-raf kinase in complex with birb796
• 4KSP: crystal structure of human b-raf bound to a dfg-out inhibitor tak-632
• 4KSQ: crystal structure of human b-raf bound to a dfg-out inhibitor 5b
• 4MBJ: human b-raf kinase domain in complex with an imidazopyridine-based inhibitor
• 4MNE: crystal structure of the braf:mek1 complex
• 4MNF: crystal structure of braf-v600e bound to gdc0879
• 4PP7: highly potent and selective 3-n-methylquinazoline-4(3h)-one based inhibitors of b-rafv600e kinase
• 4R5Y: the complex structure of braf v600e kinase domain with a novel braf inhibitor
• 4RZV: crystal structure of the braf (r509h) kinase domain monomer bound to vemurafenib
• 4RZW: crystal structure of braf (r509h) kinase domain bound to az628
• 4WO5: crystal structure of a braf kinase domain monomer
• 4XV1: b-raf kinase v600e oncogenic mutant in complex with plx7904
• 4XV2: b-raf kinase v600e oncogenic mutant in complex with dabrafenib
• 4XV3: b-raf kinase v600e oncogenic mutant in complex with plx7922
• 4XV9: b-raf kinase domain in complex with plx5568
• 4YHT: braf complexed with an inhibitor
• 5C9C: crystal structure of braf(v600e) in complex with ly3009120 compnd
• 5CSW: b-raf in complex with dabrafenib
• 5CSX: crystal structure of b-raf in complex with bi 882370
• 5CT7: braf in complex with raf265
• 5FD2: b-raf wild-type kinase domain in complex with a purinylpyridinylamino- based inhibitor
• 5HI2: braf kinase domain b3ac loop deletion mutant in complex with sorafenib
• 5HID: braf kinase domain b3ac loop deletion mutant in complex with az628
• 5HIE: braf kinase domain b3ac loop deletion mutant in complex with dabrafenib
• 5ITA: crystal structure of braf kinase domain bound to az-vem
• 5J17: solution structure of ras binding domain (rbd) of b-raf
• 5J18: solution structure of ras binding domain (rbd) of b-raf complexed with rigosertib (complex i)
• 5J2R: solution structure of ras binding domain (rbd) of b-raf
• 5JRQ: brafv600e kinase domain in complex with chemically linked vemurafenib inhibitor vem-6-vem
• 5JSM: brafv600e kinase domain in complex with chemically linked vemurafenib inhibitor vem-3-vem
• 5JT2: brafv600e kinase domain in complex with chemically linked vemurafenib inhibitor vem-bisamide
• 5VAL: braf in complex with n-(3-(tert-butyl)phenyl)-4-methyl-3-(6- morpholinopyrimidin-4-yl)benzamide
• 5VAM: braf in complex with raf709
• 5VR3: crystal structure of the brs domain of braf
• 5VYK: crystal structure of the brs domain of braf in complex with the cc-sam domain of ksr1
• 6B8U: crystals structure of b-raf kinase domain in complex with an imidazopyridinyl benzamide inhibitor
• 6CAD: crystal structure of raf kinase domain bound to the inhibitor 2a
• 6N0P: braf in complex with n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4- yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (lxh254)
• 6N0Q: braf in complex with n-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1h- benzo[d]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide.
• 6NSQ: crystal structure of braf kinase domain bound to the inhibitor 2l
• 6NYB: structure of a mapk pathway complex
• 6P3D: the co-crystal structure of braf(v600e) with ponatinib
• 6P7G: the co-crystal structure of braf(v600e) with phi1
• 6PP9: crystal structure of braf:mek1 complex
• 6Q0J: structure of a mapk pathway complex
• 6Q0K: structure of a mapk pathway complex
• 6Q0T: structure of a mapk pathway complex
• 6U2G: braf-mek complex with amp-pcp bound to braf
• 6U2H: braf dimer bound to 14-3-3
• 6UAN: b-raf:14-3-3 complex
• 6UUO: crystal structure of braf kinase domain bound to the protac p4b
• 6V2U: crystal structure of the insect cell-expressed wt-braf kinase in complex with dabrafenib
• 6V2V: crystal structure of the braf:mek1 kinases in complex with amppnp and pd0325901
• 6V2W: crystal structure of the braf:mek1 kinases in complex with amppnp
• 6V2X: crystal structure of the braf:mek1 kinases in complex with amppnp and binimetinib
• 6V2Y: crystal structure of the braf:mek1 kinases in complex with amppnp and trametinib
• 6V2Z: crystal structure of the braf:mek1 kinases in complex with amppnp and cobimetinib
• 6V30: crystal structure of the braf:mek1 kinases in complex with amppnp and pimasertib
• 6V31: crystal structure of the braf:mek1 kinases in complex with amppnp and ch5126766
• 6V32: crystal structure of the braf:mek1 kinases in complex with amppnp and selumetinib
• 6V34: crystal structure of braf v600e oncogenic mutant in complex with tak- 580
• 6XAG: apo braf dimer bound to 14-3-3